The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS).
 
Andrew Mark Haydon
Honoraria - Merck; Novartis; Novartis
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; Merck; Novartis
 
Nikhil I. Khushalani
Stock and Other Ownership Interests - Amarin Corporation; Asensus Surgical; Bellicum Pharmaceuticals
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Castle Biosciences; Genzyme; Immunocore; Incyte; Instil Bio; Iovance Biotherapeutics; Jounce Therapeutics; Merck; NCCN/Pfizer; Nektar; Novartis; Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); HUYA Bioscience International (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst); Replimune (Inst)
Other Relationship - Bristol-Myers Squibb/Celgene; Nektar; Regeneron
 
Caroline Robert
Stock and Other Ownership Interests - RiboNexus
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Research Funding - Novartis (Inst)
 
Daniel Brungs
No Relationships to Disclose
 
Frances A. Collichio
Research Funding - Amgen (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); REPLIMUNE (Inst)
Other Relationship - ACGME
 
A. Dimitrios Colevas
Consulting or Advisory Role - Alpha BioCom; Beigene; ClearView Healthcare Partners; Deallus; Gilead Sciences; leidos biomedical research
Research Funding - Abbvie; AstraZeneca; Atara Biotherapeutics; BioNtech; BMS; CUE Biopharma; Cullinan Oncology; Exelixis; Experimental Therapeutics Clinical Trials Network (ETCTN); Forty Seven; Innate Pharma; Merck; NIH/NCI; NRG Oncology; Tessa Therapeutics
 
Annette May Ling Lim
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Ragini Reiney Kudchadkar
Honoraria - Array BioPharma; Bristol-Myers Squibb; Genentech; Merck; Novartis; Pfizer; Sanofi/Regeneron
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Immunocore; Merck; Novartis; Regeneron
Research Funding - Bristol-Myers Squibb/Ono Pharmaceutical; Merck (Inst); Regeneron (Inst)
 
Wanxing Chai-Ho
Consulting or Advisory Role - SERVIER
 
Gregory A. Daniels
Honoraria - Bayer; Blueprint Medicines
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Nektar (Inst); Viralytics (Inst)
 
Jose Lutzky
Consulting or Advisory Role - Castle Biosciences; Eisai; Iovance Biotherapeutics; Sapience Therapeutics
Research Funding - BioNTech (Inst); Bristol-Myers Squibb (Inst); Day One Biopharmaceuticals (Inst); Dragonfly Therapeutics (Inst); Foghorn Therapeutics (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); InflarxGmbH (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Novartis (Inst); Regeneron (Inst); Replimune (Inst); Ultimovacs (Inst); Vyriad (Inst)
 
Jenny HJ Lee
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD
Consulting or Advisory Role - Sanofi
Travel, Accommodations, Expenses - Bio-Rad; Bristol-Myers Squibb; Novartis
 
Ann W. Silk
Consulting or Advisory Role - Genzyme; Instil Bio; Merck; Oncosec
Research Funding - Biohaven Pharmaceuticals (Inst); Morphogenesis (Inst); Replimune (Inst); Shattuck Labs (Inst)
 
Celeste Lebbe
Honoraria - Amgen; Bristol-Myers Squibb; Incyte; MSD; Novartis; Pfizer; Pierre Fabre; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Sanofi
Other Relationship - Avantis Medical Systems
 
Jean-Jacques Grob
Consulting or Advisory Role - Amgen; BMS; Merck KGaA; MSD Oncology; Novartis; Philogen; Pierre fabre; Roche; Roche/Genentech; Sanofi; Sun Pharma
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - BMS; MSD Oncology; Novartis; Pierre Fabre
 
Margaret Smith
Employment - Replimune
Stock and Other Ownership Interests - Replimune
 
Matthew G. Fury
Employment - Regeneron; Regeneron (I)
Stock and Other Ownership Interests - Regeneron; Regeneron (I)
Research Funding - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneorn; Regeneron (I)
 
Muhammad Alamgeer
No Relationships to Disclose
 
Andrew Graham Hill
Employment - Tasman Oncology
Stock and Other Ownership Interests - Tasman Oncology
 
Michael Robert Migden
Honoraria - Regeneron; Sanofi
Consulting or Advisory Role - Replimune; Sanofi; Sun Pharma